ASX healthcare shares have been among the top-performing market sectors over the last 12 months. The demand for healthcare products and services continues to grow higher around the world.
CSL has evolved over the past 3 decades to become a global market leader in blood plasma research and disease treatment. The company is now a highly successful global business that provides a broad range of research treatments that are protected by product patents. This is backed by a highly efficient global production and distribution network, reaching more than 60 countries. CSL delivered a very strong 11% increase in revenue to US$4,980 million for the six months to 31 December 2019
This ASX healthcare share has also played a vital role during the coronavirus pandemic. It recently entered into a new agreement for the development of a COVID-19 vaccine candidate.
I believe that the CSL growth story is set to continue over the next decade, driven by a strong new product development pipeline. With its share price down by around 18% on its 12-month high in February, I feel that now could be a good time to add CSL shares to your ASX portfolio.
Another company that appeals to me in the ASX healthcare sector right now is Cochlear.
The Cochlear share price fell heavily during the early phase of the coronavirus pandemic. Since then, it has only seen a relatively weak and partial recovery. Cochlear’s shares are still down by around 25% from mid February. There has been a sharp reduction in elective surgeries in is operating markets, particularly in the United States and Western Europe. However, elective surgeries are now beginning again in some markets including Australia. I think that the significant recent reduction in the Cochlear share price provides investors with a good buying opportunity. I remain confident about Cochlear’s long term future, driven by the growing demand for quality hearing products and solutions over the next few decades.
Both CSL and Cochlear are two quality ASX healthcare shares that I think would make good buy and hold options over the next five years. I believe both are well placed to deliver above average shareholder returns during this period. With recent reductions in their share prices since the onset of the pandemic, investors have the opportunity to snap them up at more attractive prices.
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
Phil Harpur owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Why I’d buy Wesfarmers and 1 other quality ASX dividend right now – August 31, 2020 12:30pm
- Elixinol share price edges higher on half year earnings release – August 31, 2020 11:54am
- 2 top ASX tech shares to buy and hold beyond 2025 – August 28, 2020 8:33am